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PCardiovascular Mortality in
Chronic Kidney Disease Patients Undergoing
Percutaneous Coronary Intervention Is Mainly
Related to Impaired P2Y12 Inhibition by Clopidogrel
Olivier Morel, MD, PHD,*† Soraya El Ghannudi, MD,* Laurence Jesel, MD,* Bogdan Radulescu, MD,*
Nicolas Meyer, MD, PHD,‡ Marie-Louise Wiesel, MD,§ Sophie Caillard, MD, PHD,
Umberto Campia, MD,¶ Bruno Moulin, MD, PHD, Christian Gachet, MD, PHD,§
Patrick Ohlmann, MD, PHD*
Strasbourg and Le Kremlin Bicêtre, France; and Chicago, Illinois
Objectives We sought to determine whether low platelet response to the P2Y12 receptor antagonist clopidogrel as as-
sessed by vasodilator-stimulated phosphoprotein flow cytometry test (VASP-FCT) differentially affects out-
comes in patients with or without chronic kidney disease (CKD) undergoing percutaneous coronary interven-
tion (PCI).
Background Although both CKD and impaired platelet responsiveness to clopidogrel are strong predictors of unfavorable
outcome after PCI, the impact of their association is unknown. The platelet VASP-FCT assay is specific for
the P2Y12 ADP receptor pathway. In this test, platelet activation is expressed as the platelet reactivity index
(PRI).
Methods Four-hundred forty unselected patients (CKD: 126, estimated glomerular filtration rate [eGFR] 60 ml/min/1.73
m2), no-CKD: 314 eGFR 60 ml/min/1.73 m2) undergoing urgent (n  336) or planned (n  104) PCI were
prospectively enrolled. In each subgroup, patients were classified as low-responders (LR: PRI 61%) or respond-
ers (R: PRI 61%) to clopidogrel.
Results At a mean follow-up of 9  2 months, all-cause mortality, cardiac death, and possible stent thrombosis were
higher in CKD than in no-CKD patients. Within the CKD group, the LR status was associated with higher rates of
all-cause mortality (25.5% vs. 2.8%, p  0.001), cardiac death (23.5% vs. 2.8%, p  0.001), all stent thrombo-
sis (19.6% vs. 2.7%, p  0.003), and MACE (33.3% vs. 12.3%, p  0.007). Conversely, in no-CKD patients, the
LR status did not affect outcomes. Multivariate analysis identified Killip class 3, drug-eluting stent implanta-
tion, and the interaction between LR and CKD (hazard ratio: 11.96, 95% confidence interval: 1.22 to 116.82;
p  0.033) as independent predictors of cardiac death.
Conclusions In CKD patients, the presence of low platelet response to clopidogrel is associated with worse outcomes after
PCI. (J Am Coll Cardiol 2011;57:399–408) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.032a
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lhe combined pharmacological inhibition of the P2Y12
eceptor by thienopyridines and of the cyclooxygenase
athway by aspirin is currently considered the reference
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ccepted September 28, 2010.ntiplatelet strategy to minimize the risk of thrombotic
omplications following percutaneous coronary interven-
ions (PCI) (1,2). However, significant variability exists in
he rate of platelet inhibition with this therapy, and an
mpaired platelet responsiveness to clopidogrel may be
ssociated with worse cardiovascular outcomes in patients
reated by PCI (3–5).
Patients with chronic kidney disease (CKD) present with
ccelerated atherosclerosis and higher cardiovascular mor-
idity and mortality (6 –11). Furthermore, CKD is asso-
iated with adverse outcome following PCI (12–14),
ikely related to endothelial dysfunction, inflammation,
nd platelet activation. However, whether an impaired
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P2Y12 Inhibition in CKD and Outcomes After PCI January 25, 2011:399–408platelet inhibition to clopidogrel
is an independent predictor of
cardiovascular outcomes in pa-
tients with CKD remains un-
known. The present study was
therefore designed to test the
hypothesis that low platelet re-
sponsiveness to clopidogrel, as
assessed by vasodilator stimu-
lated phosphoprotein (VASP)
phosphorylation, independently
contributes to adverse cardiovas-
cular events after PCI in patients
with CKD.
Methods
Patients. This study enrolled
consecutive patients undergoing
PCI for an acute coronary syn-
drome or stable coronary artery
isease in our institution between September 2007 and
ecember 2008. The study was performed in accordance
ith the Declaration of Helsinki. The protocol was ap-
roved by the institutional ethics committee, and informed
ritten consent was obtained from all patients.
enal function staging. Baseline serum creatinine levels
ere assessed at admission in all patients. The estimated
lomerular filtration rate (eGFR) was calculated using the
bbreviated MDRD (Modification of Diet in Renal Dis-
ase) formula according to Levey et al. (15). Patients were
ivided into 4 subgroups according to their eGFR levels:
90 ml/min/1.73 m2; 60 and 89 ml/min/1.73 m2; 30
nd 59 ml/min/1.73 m2; and 30 ml/min/1.73 m2).
atients with an eGFR 60 ml/min/1.73 m2 were assigned
o the CKD group, whereas those with an eGFR 60
l/min/1.73 m2 were assigned to the no-CKD group.
lood samples. Whole blood samples were collected by
enipuncture at least 6 h after a loading dose (300 or 600
g) of clopidogrel. Blood was collected into Vacutainer
ubes containing 0.129 M sodium citrate (BD Vacutainer,
ecton Dickinson, Sparks, Maryland) and immediately sent
o the hemostasis laboratory (EFS-Alsace).
nalysis of VASP phosphorylation by flow cytometry.
ost-PCI platelet VASP phosphorylation was assessed in all
atients using a standardized flow cytometric assay (Platelet
ASP, Biocytex, Diagnostica Stago, Asnières, France) as
reviously described (16). Levels of VASP phosphorylation
eflect P2Y12 inhibition and are expressed as the platelet
eactivity index (PRI), calculated from the median fluores-
ence intensity (MFI) of samples incubated with prosta-
landin E1 (PGE1) or PGE1 and ADP according to the
ormula: PRI [(MFIPGE1MFIPGE1ADP)/MFIPGE1]
00 (16). The advantages of the VASP assay are its
Abbreviations
and Acronyms
CKD  chronic kidney
disease
DES  drug-eluting stent(s)
eGFR  estimated
glomerular filtration rate
MACE  major adverse
cardiac events
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
VASP  vasodilator-
stimulated phosphoproteinelectivity for the P2Y12 pathway, its insensitivity toward wlycoprotein IIb/IIIa inhibitors, the stability of the results
or more than 24 h after blood sampling, and the interpret-
bility of single measurements (17). In unselected patients
ndergoing PCI, we recently found that the optimal cutoff
alue for PRI to predict cardiovascular outcome following
CI was 61% using a receiver-operating characteristic curve
nalysis based on the maximal value of the Youden index
18). Therefore, patients were considered to have a low
latelet response to clopidogrel (low responders) if their PRI
as 61%, and a normal response to clopidogrel (respond-
rs) if their PRI was 61%.
linical end points. The primary end points of the study
ere all-cause mortality, cardiovascular mortality (defined as
ny death with demonstrable cardiovascular cause or any
eath that was not clearly attributable to a noncardiovascu-
ar cause), ST-segment elevation myocardial infarction
STEMI, defined as a new or presumably new ST-segment
levation in 2 consecutive leads associated with an increase
n biochemical markers of myocardial necrosis), and non–
T-segment elevation myocardial infarction (NSTEMI,
efined as the occurrence of ischemic symptoms, ST-
egment depression and/or T-wave abnormalities, and an
ncrease of biochemical markers of myocardial necrosis).
ost-PCI troponin (Tn) elevations were not considered as
ndicating a recurrent myocardial infarction. Secondary
nd points included: definite/probable stent thrombosis,
ossible stent thrombosis, all stent thrombosis, and major
dverse cardiac events (MACE), defined as the composite
f all-cause mortality, nonfatal myocardial infarction, or
arget lesion revascularization. The diagnosis of stent
hrombosis was defined according to the Academic Re-
earch Consortium criteria as follows: definite  acute
oronary syndrome and angiographic or pathologic evi-
ence of stent thrombosis; probable  unexplained death
ithin 30 days or target vessel infarction without angio-
raphic information; and possible  unexplained death
fter 30 days of stent placement. Follow-up data were
btained through a questionnaire sent to the patients’
ardiologists or referring physicians and collected by
hone. End points were adjudicated by 2 independent
hysicians who were blind to PRI values.
tatistical analysis. Continuous variables are expressed as
edian (interquartile range); categorical variables are ex-
ressed as frequencies and percentages. Continuous vari-
bles between 2 groups were compared by Student t test or
y Mann-Whitney test as appropriate. Fisher exact test was
sed for comparison of categorical variables. Continuous
ariables were analyzed for normal distribution using the
hapiro-Wilk test. Time to event was defined as the time
rom PCI to the date of event, with patients censored at
eath, loss to follow-up, or end of the study (June 30, 2009).
aplan-Meier analyses were used to construct survival plots
f time to death after PCI and compared using log-rank
est. Multivariate analysis of survival rates was done using
ox models. Variables with p  0.05 in univariate analysis
ere entered into a stepwise ascending multivariate analysis.
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January 25, 2011:399–408 P2Y12 Inhibition in CKD and Outcomes After PCIo evaluate a differential effect of low response to
lopidogrel in the presence or in the absence of CKD, an
nteraction term between these 2 terms was introduced in
he model, in addition to the 2 main effects of these
ariables. The results of the Cox regression are presented
s hazard ratios (HR), their 95% confidence intervals
CIs), and p values. A p value 0.05 was considered
tatistically significant. Statistical analysis was performed
sing SPSS version 13.0 software (SPSS Inc., Chicago,
llinois).
esults
aseline characteristics and biological response to clopi-
ogrel. A total of 440 consecutive patients treated by
lanned (n  104, 23.6%) or urgent PCI (n  336, 76.3%)
ere enrolled in this study. Of them, 314 had eGFR 60
l/min/1.73 m2 (no-CKD group), and 126 had eGFR60
l/min/1.73 m2 (CKD group). Baseline demographics
nd clinical, biological, and angiographic characteristics
f the 2 groups are described in Tables 1, 2, and 3. The
ajority (n  104, 82.5%) of CKD patients had an
GFR between 30 and 59 ml/min/1.73 m2 (stage III
KD according to the National Kidney Foundation
idney Disease Outcome Quality Initiative), whereas the
emaining CKD patients (n  22, 17.4%) had an eGFR
etween 15 and 29 ml/min/1.73 m2 (stage IV CKD). As
aseline Demographic and Clinical Characteristics According to ReTable 1 Baseline Demographic and Clinical Characteristics Acc
No CKD (n  314)
Variable
Responders
(n  188)
Low Responders
(n  126)
Age, yrs 65.5 (57.5–75.9) 62.5 (53–71)
Male sex 155 (82.4) 105 (83.3)
Current smoking 116 (61.7) 64 (50.8)
Hypertension 82 (43.6) 66 (52.4)
Obesity (BMI 30 kg/m2) 70 (37.6) 65 (51.5)
Hyperlipidemia 90 (47.9) 69 (54.8)
Diabetes 54 (28.7) 52 (41.3)
Prior STEMI 30 (16) 16 (12.7)
Prior stroke 10 (5.3) 4 (3.2)
STEMI 59 (31.4) 49 (38.9)
NSTEMI 66 (35.1) 33 (26.2)
Unstable angina 19 (10.1) 11 (8.7)
Planned PCI 44 (23.4) 32 (25.4)
Treatment
Aspirin  clopidogrel 188 (100) 126 (100)
Clopidogrel dose, mg 450 (375–675) 450 (300–600)
Beta-blockers 180 (95.7) 122 (96.8)
Statin 183 (97.3) 125 (99.2)
Oral anticoagulants 7 (3.7) 10 (7.9)
GP IIb/IIIa antagonists 36 (19.1) 42 (33.3)
Proton pump inhibitors 133 (70.7) 86 (68.3)
Calcium-channel blockers 6 (3.2) 3 (2.4)
ACE inhibitors 184 (97.9) 123 (97.6)
ata are expressed as median (interquartile range) or n (%).
ACE  angiotensin-converting enzyme; BMI  body mass index; CKD  chronic kidney disease; GP 
oronary intervention; STEMI  ST-segment elevation myocardial infarction.xpected, diabetes mellitus was more prevalent among
KD patients than in patients with normal renal func-
ion (46.8% vs. 33.8%, respectively; p  0.012). Among
ll patients, 261 had normal platelet response to clopi-
ogrel (188 in the no-CKD group and 73 in the CKD
roup), and 179 had low platelet response (126 in the
o-CKD group and 53 in the CKD group).
The time elapsed between the administration of the
lopidogrel loading dose and VASP measurement was 12
in 66 patients (15%), between 12 and 24 h in 165 patients
37.5%), between 24 and 48 h in 66 patients (15%), between
8 and 72 h in 60 patients (13.6%), and 72 h in 83
atients (18.8%). The delay between clopidogrel loading
ose and VASP assay was similar between the low re-
ponder and responder groups, and between the CKD and
o-CKD groups.
The median value of PRI (%) was not significantly
ifferent between the CKD and the no-CKD groups (55.8
25th to 75th percentile: 40.3 to 70.2] vs. 55.7 [25th to 75th
ercentile: 35.5 to 70.4]; p  0.534). In each of these 2
roups, patients were divided into 2 separate subgroups
ccording to a PRI cutoff value of 61%. The proportion of
ow responder patients was similar between the CKD and
o-CKD groups (42.0% vs. 40.1%, respectively; p 0.748).
ikewise, the cumulative clopidogrel dose (total dose re-
eived prior to testing) did not differ. The proportion of
unction and Platelet Response to Clopidogrelg to Renal Function and Platelet Response to Clopidogrel
CKD (n  126)
p Value
Responders
(n  73)
Low Responders
(n  53) p Value
0.055 69 (59–76) 66 (56–78) 0.783
0.880 40 (54.8) 33 (62.3) 0.466
0.063 20 (27) 17 (32.1) 0.692
0.135 57 (78.1) 34 (64.2) 0.108
0.014 35 (49.3) 27 (51.9) 0.856
0.251 44 (60.3) 28 (52.8) 0.467
0.028 32 (43.8) 27 (50.9) 0.472
0.515 13 (17.8) 15 (28.3) 0.195
0.418 3 (4.1) 3 (5.7) 0.82
0.184 18 (24.7) 20 (37.7) 0.122
0.108 30 (41.1) 20 (37.7) 0.717
0.840 5 (6.8) 6 (11.3) 0.525
0.689 21 (28) 7 (13.2) 0.050
1.000 73 (100) 53 (100) 1.000
0.165 450 (300–675) 375 (300–675) 0.869
0.768 71 (97.3) 48 (90.6) 0.130
0.408 71 (97.3) 50 (94.3) 0.649
0.129 5 (6.8) 5 (9.4) 0.741
0.005 12 (16.4) 15 (28.3) 0.127
0.707 56 (76.7) 32 (60.4) 0.053
0.745 6 (8.2) 6 (11.3) 0.558
1.000 70 (95.9) 50 (94.3) 0.695nal Fordinglycoprotein; NSTEMI  non–ST-segment elevation myocardial infarction; PCI  percutaneous
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P2Y12 Inhibition in CKD and Outcomes After PCI January 25, 2011:399–408tage IV patients was not statistically different between the
esponder and low responder subgroups (13.7% vs. 22.6%,
espectively; p  0.237).
mpact of CKD on cardiovascular outcomes. Clinical
utcomes were available in 433 of 440 patients (98.4%),
ith a mean follow-up of 9  2 months (range 6 to 14
onths). At follow-up, the rate of dual antiplatelet therapy
as lower in CKD patients compared with those with
ormal renal function (79.4% vs. 89.2%, respectively; p 
.018). Compared with those with preserved eGFR, pa-
ients with CKD had significantly higher all-cause and
ardiovascular mortality (p  0.001 and p  0.001, respec-
ively) as well as increased incidence of possible stent
hrombosis (Fig. 1, Table 4). A total of 23 all stent
hrombosis was recorded in the cohort, which occurred
etween 4 and 375 days after PCI. Of these, 5 occurred
ithin the first 30 days. No difference in the time of
aboratory Parameters According to Renal Function and Platelet RTable 2 Laboratory Parameters According to Renal Function an
No CKD (n  314)
Responders
(n  188)
Low Responders
(n  126)
Blood glucose, g/l 1.10 (0.95–1.50) 1.30 (1.07–1.61)
HbA1C, % 6 (5.50–7.27) 6.2 (5.7–8.3)
Uremia, mmol/l 5.70 (4.80–7.25) 6.2 (4.9–7.4)
Creatinine, mol/l 76.1 (65.20–89.75) 82 (71–94)
Creatinine clearance 90 (75–106) 83 (72–100)
Tn admission, g/l 0.19 (0.08–0.69) 0.36 (0.14–2.09)
Tn H6, g/l 0.61 (0.14–4.87) 3.49 (0.14–36.40)
Tn peak, gl/l 3.84 (0.24–31.24) 16.50 (2.2–48.1)
CPK, U/l 125 (72–288) 215 (102–611)
BNP, ng/l 97 (41–238) 71 (27–144)
CRP, mg/l 4.5 (4.0–10.8) 5.6 (4.0–16.2)
WBC,  109/l 8.58 (7.09–10.84) 9.20 (6.90–11.00)
Hb, g/dl 13.7 (12.6–14.8) 13.8 (12.7–14.8)
Platelets,  109/l 240 (188.5–285.5) 237 (182–292
Total cholesterol, mmol/l 1.74 (1.49–2.10) 1.8 (1.52–2.14)
LDL-C, mmol/l 1.09 (0.81–1.41) 1.10 (0.85–1.42)
HDL-C, mmol/l 0.40 (0.30–0.50) 0.40 (0.30–0.40)
TG, mmol/l 1.19 (0.80–1.64) 1.29 (0.91–1.85)
PRI, % 40.80 (25.30–50.40) 73 (66–79)
ata are expressed as median (interquartile range).
BNP  brain natriuretic peptide; CKD  chronic kidney disease; CPK  creatinine phosph
DL-C  low-density lipoprotein cholesterol; PRI  platelet reactivity index; TG  triglycerides; Tn
ngiographic and Procedural Characteristics According to Renal FuTable 3 Angiographic and Procedural Characteristics According
No CKD (n  314)
Responders
(n  188)
Low Responders
(n  126)
LAD 125 (66.4) 84 (66.7)
Left main coronary artery 13 (6.9) 6 (4.8)
3-vessel disease 42 (22.3) 42 (33.3)
Stenting 177 (94.1) 117 (92.9)
Drug-eluting stent 91 (48.4) 52 (41.2)
Stent length 30 mm 7 (3.7) 7 (5.6)alues are n (%)
CKD  chronic kidney disease; LAD  left anterior descending artery.ccurrence of stent thrombosis was observed between the
groups.
mpact of P2Y12 inhibition by clopidogrel on cardiovascular
utcomes. In the whole population, the presence of a LR
tatus was associated with higher rates of all-cause mortality
s well as of possible and all stent thrombosis (Table 5).
nteraction between baseline renal function and degree
f P2Y12 inhibition by clopidogrel on cardiovascular
utcomes. In the no-CKD group, no statistically signif-
cant differences in any of the primary and secondary end
oints were observed between patients with normal and
hose with low response to clopidogrel (Table 6). In
ontrast, among patients with CKD, the incidence of
ll-cause mortality, cardiovascular mortality, possible
tent thrombosis, all stent thrombosis, and MACE was
ignificantly higher in the low responders compared with
he responder subgroup (Table 6, Figs. 2 and 3). To gain
nsiveness to Clopidogreltelet Responsiveness to Clopidogrel
CKD (n  126)
p Value
Responders
(n  73)
Low Responders
(n  53) p Value
0.002 1.30 (0.95–1.93) 1.28 (1.01–1.94) 0.868
0.135 6.60 (5.90–7.40) 6.60 (6.02–7.37) 0.993
0.439 9 (7.40–14.00) 10 (7.6–14.3) 0.406
0.134 125 (109–159) 142 (118–180) 0.070
0.110 48 (36–54) 42 (31.5–53.0) 0.205
0.016 0.44 (0.08–1.24) 0.51 (0.14–1.21) 0.387
0.012 1.31 (0.15–11.00) 2.28 (0.24–19.63) 0.355
0.010 9.61 (1.73–21.71) 4.25 (0.40–71.33) 0.764
0.009 235 (99–359) 198 (68–491) 0.825
0.133 299 (99–815) 321 (93–591) 0.635
0.082 9.95 (4.03–36.83) 11.9 (4–32.60) 0.783
0.758 8.73 (7.38–12.70) 10.0 (7.50–11.49) 0.366
0.701 12.10 (10.30–13.58) 12.30 (10.65–14.13) 0.485
0.608 248 (207–298) 251 (214–310) 0.570
0.434 1.59 (1.31–1.86) 1.65 (1.29–2.24) 0.331
0.947 0.95 (0.70–1.14) 0.89 (0.65–1.52) 0.809
0.080 0.40 (0.30–0.50) 0.40 (0.30–0.50) 0.799
0.107 1.03 (0.71–1.48) 1.17 (0.97–1.84) 0.127
0.001 43.1 (29.9–57.5) 72.8 (65.6–79.0) 0.001
; CRP  C-reactive protein; Hb  hemoglobin; HDL-C  high-density lipoprotein cholesterol;
onin; Tn H6  troponin 6 h after admission; WBC  white blood cell count.
n and Platelet Responsiveness to Clopidogrelenal Function and Platelet Responsiveness to Clopidogrel
CKD (n  126)
p Value
Responders
(n  73)
Low Responders
(n  53) p Value
0.903 59 (80.8) 36 (67.9) 0.142
0.480 7 (9.6) 11 (20.8) 0.120
0.037 28 (38.4) 22 (41.5) 0.854
0.806 70 (95.9) 52 (98.1) 0.638
0.343 33 (45.2) 27 (50.9) 0.715
0.578 0 (0) 3 (5.7) 0.072espod Planctioto R
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January 25, 2011:399–408 P2Y12 Inhibition in CKD and Outcomes After PCInsight into the relationship between PRI levels and
ACE among CKD patients, data were also analyzed
ccording to quartiles of PRI (Table 7). At the end of
ollow-up, the proportion of patients on dual antiplatelet
herapy in the CKD group was similar between low
esponder and responder patients (85.5% and 87%, re-
pectively; p  0.371).
redictors of cardiac death and MACE. By univariate
ox analysis, Killip class III to IV, the use of drug-eluting
tents (DES), a diagnosis of CKD, and a low response to
lopidogrel (PRI 61%) were significant predictors of
ardiac death (Table 8). The occurrence of MACE was
irectly related to Killip class III to IV, the use of DES,
nd the presence of 3-vessel disease, whereas planned
CI was associated with a lower risk of MACE. Multi-
Figure 1 Kaplan-Meier Analysis for
the Probability of Cardiac Survival
Kaplan-Meier analysis for the probability of cardiac survival according to the
absence or presence of chronic kidney disease (CKD).
utcomes at Follow-Up According to Baseline Renal FunctionTable 4 Outcomes at Follow-Up According to Baseline Renal Fu
No CKD (n  309)
eGFR (ml/min/1.73 m2)
>90 (n  140) 60–90
All-cause mortality 2 (1.4) 8
Cardiac death 1 (0.7) 5
STEMI 2 (1.4) 2
NSTEMI 9 (6.4) 9
TLR 14 (10) 19
Definite/probable stent thrombosis 4 (2.9) 6
Possible stent thrombosis 1 (0.7) 0
All stent thrombosis 5 (3.6) 6
MACE 19 (13.6) 26ata are expressed as n (%) unless specified otherwise. Follow-up was obtained in 433 of 440 patients.
eGFR  estimated glomerular filtration rate; MACE  major cardiovascular events; TLR  target lesioariate Cox regression analysis identified Killip III to IV,
he use of DES, and the interaction between CKD and
ow response to clopidogrel as independent predictors of
ardiac death (Table 9). In contrast, the interactions
etween a diagnosis of type 2 diabetes and low responder
r type 2 diabetes and CKD were not independent
redictors of cardiac death.
iscussion
he main finding of this study is that the presence of low
latelet response to clopidogrel is associated with increased
ll-cause mortality, cardiac death, possible and all stent
hrombosis, and MACE after PCI in patients with CKD.
owever, in patients with preserved eGFR, these outcomes
o not appear to differ between those with normal and those
ith reduced platelet response to clopidogrel. In addition,
ur data confirm the association between the presence of
KD and worse all-cause mortality and cardiovascular
utcomes.
Several studies in the setting of STEMI (19), NSTEMI,
nd elective PCI (20,21) have reported a negative associa-
ion between CKD and stent thrombosis, post-procedure
on
CKD (n  124)
eGFR (ml/min/1.73 m2)
69) 30–59 (n  103) <30 (n  21) p Value
11 (10.7) 4 (19) 0.001
10 (9.7) 4 (19) 0.001
3 (2.9) 1 (4.8) 0.537
4 (3.9) 1 (4.8) 0.855
8 (7.8) 1 (4.8) 0.683
5 (4.9) 2 (9.5) 0.481
4 (3.9) 1 (4.8) 0.026
9 (8.7) 3 (14.3) 0.054
19 (18.4) 7 (33.3) 0.130
utcomes According tolatelet Responsiveness to ClopidogrelTable 5 Outcomes According toPlatelet Responsiveness to Clopidogrel
Responder
(n  260)
Low Responder
(n  173) p Value
All-cause mortality 9 (3.5) 16 (9.2) 0.019
Cardiac death 6 (2.3) 14 (8.1) 0.008
STEMI 5 (1.9) 3 (1.7) 1.000
NSTEMI 12 (4.6) 11 (6.4) 0.513
TLR 24 (9.2) 18 (10.4) 0.741
Definite stent thrombosis 4 (1.5) 5 (2.9) 0.494
Probable stent thrombosis 3 (1.2) 5 (2.9) 0.275
Definite/probable stent thrombosis 7 (2.7) 10 (5.8) 0.131
Possible stent thrombosis 1 (0.4) 5 (2.9) 0.040
All stent thrombosis 8 (3.1) 15 (8.7) 0.015
MACE 36 (13.8) 35 (20.2) 0.086
ata are expressed as n (%) unless specified otherwise.
Abbreviations as in Tables 1 and 4.ncti
(n  1
(4.7)
(3)
(1.2)
(5.3)
(11.2)
(3.6)
(0)
(3.6)
(15.4)n revascularization; other abbreviations as in Table 1.
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12,19–24). In a large retrospective analysis, the presence of
ecreased renal function had a similar negative impact on
ortality and morbidity as diabetes mellitus (12). In our
nvestigation, the increase in all-cause and in cardiovascular
eath rates observed in the participants with CKD is in line
utcomes According to Renal Function and Platelet ResponsivenesTable 6 Outcomes According to Renal Function and Platelet R
No CKD (n  309
Responder
(n  187)
Low Responde
(n  122)
All-cause mortality 7 (3.7) 3 (2.5)
Cardiac death 4 (2.1) 2 (1.6)
STEMI 3 (1.6) 1 (0.8)
NSTEMI 10 (5.3) 8 (6.6)
TLR 19 (10.2) 14 (11.5)
Definite stent thrombosis 3 (1.6) 4 (3.2)
Probable stent thrombosis 2 (1.1) 1 (0.8)
Definite/probable stent thrombosis 5 (2.7) 5 (4)
Possible stent thrombosis 1 (0.5) 0 (0)
All stent thrombosis 6 (3.2) 5 (4)
MACE 27 (14.4) 18 (14.8)
ata are expressed as n (%) unless specified otherwise.
Abbreviations as in Tables 1 and 4.
Figure 2 Kaplan-Meier Analysis for
the Probability of Cardiac Survival
Kaplan-Meier analysis for the probability of cardiac survival according to the
absence or presence of chronic kidney disease (CKD) and to the level of plate-
let P2Y12 inhibition by clopidogrel, expressed as the platelet reactivity index
(PRI).ith a previous report of a 5-fold higher mortality at 1 year
ost-PCI in patients with moderate renal insufficiency (12).
owever, it should be emphasized that this latter study had
nrolled lower-risk patients. By comparison, our study
opulation mainly consisted of CKD patients with acute
oronary syndrome patients (30.1% with STEMI and
9.6% with NSTEMI). In the setting of acute myocardial
nfarction, 1-year mortality rate observed in moderate CKD
Clopidogrelsiveness to Clopidogrel
CKD (n  124)
p Value
Responder
(n 73)
Low Responder
(n  51) p Value
0.745 2 (2.8) 13 (25.5) 0.001
1.000 2 (2.8) 12 (23.5) 0.001
1.000 2 (2.8) 2 (3.9) 1.000
0.804 2 (2.8) 3 (5.9) 0.640
0.711 5 (6.9) 4 (7.8) 1.000
0.443 1 (1.4) 1 (1.9) 1.000
1.000 1 (1.4) 4 (7.8) 0.158
0.527 2 (2.7) 5(9.8) 0.123
1.000 0 (0) 5 (9.8) 0.010
0.759 2 (2.7) 10 (19.6) 0.003
1.000 9 (12.3) 17 (33.3) 0.007
Figure 3 Kaplan-Meier Analysis for the
Probability of MACE Event-Free Survival
Kaplan-Meier analysis for the probability of major adverse cardiac events
(MACE) event-free survival according to the absence or presence of CKD and to
the level of platelet P2Y12 inhibition by clopidogrel, expressed as the PRI.
Abbreviations as in Figure 2.s toespon
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on-CKD patients (19). The mechanisms by which CKD
mpacts the clinical outcome are likely multifactorial, and
ay include dyslipidemia, homocysteinemia, insulin resis-
ance, increased oxidative stress, extensive coronary calcifi-
ation, endothelial damage (25), reduced number and func-
ion of endothelial progenitor cells (26), abnormal platelet–
ndothelial cell interactions, and a prothrombotic state
27–31). A reduced bioavaibility of nitric oxide (NO)
econdary to increased oxidative stress has been proposed to
lay a major role in CKD-associated endothelial dysfunc-
ion, possibly leading to enhanced vasoconstriction and
latelet adhesion/activation (32).
utcomes at Follow-Up According to PRI Quartiles in CKD PatientsTable 7 Outcomes at Follow-Up According to PRI Quartiles in C
Quartile 1
(<40.30%)
Quar
(40.30%
All-cause mortality 1 (3) 1 (3
Cardiac death 1 (3) 1 (3
STEMI 1 (3) 1 (3
NSTEMI 1 (3) 1 (3
TLR 3 (9.1) 1 (3
Definite stent thrombosis 1 (3) 0 (0
Probable stent thrombosis 0 (0) 1 (3
Definite/probable stent thrombosis 1 (3) 1 (3
Possible stent thrombosis 0 (0) 0 (0
All stent thrombosis 1 (3) 1 (3
MACE 5 (15.2) 3 (1
ata are expressed as n (%) unless specified otherwise.
Abbreviations as in Tables 1, 2, and 4.
nivariate Analysis for Prediction of Cardiac Death and MACE in thTable 8 Univariate Analysis for Prediction of Cardiac Death and
Cardiac D
HR (95% CI)
Age 1.20 (0.98–1.05)
Sex 1.97 (0.80–4.82)
Diabetes mellitus 2.16 (0.89–5.23)
Obesity 1.24 (0.51–2.99)
Hypertension 0.80 (0.33–1.93)
Hyperlipidemia 0.47 (0.19–1.20)
Smoking 0.85 (0.35–2.06)
History of STEMI/NSTEMI 1.11 (0.39–3.51)
History of unstable angina 2.81 (0.82–9.62)
CKD (eGFR 60 ml/min/1.73 m2) 5.57 (2.14–14.54)
STEMI 1.41 (0.57–3.45)
NSTEMI 1.33 (0.54–3.27)
Unstable angina 1.88 (0.55–6.43)
Planned PCI 0.03 (0.00–2.10)
Killip class III–IV 9.20 (3.66–23.12)
3-vessel disease 1.24 (0.49–3.12)
LAD 1.80 (0.60–5.38)
DES 4.82 (1.58–14.62)
Stent length 30 mm 1.64 (0.22–12.32)
PRI 61% (LR) 3.66 (1.40–9.53)I confidence interval; DES drug-eluting stent; HR hazard ratio; LAD left anterior descending coron
s in Tables 1, 2, and 4.mpact of CKD on platelet P2Y12 inhibition by clopidogrel.
hether CKD affects clopidogrel pharmacokinetics has not
een conclusively clarified. Although it has been suggested
hat the extent of platelet inhibition by clopidogrel is
omparable between patients on long-term hemodialysis
nd those with normal renal function (33), other evidence
ndicates that the lack of platelet responsiveness to clopi-
ogrel might be more pronounced in patients with CKD
34,35). In our study, the degree of P2Y12 inhibition by
lopidogrel using the VASP assay was not significantly
ifferent in the CKD and non-CKD groups. Likewise, the
roportion of LR patients was equivalent in both groups.
aken together, these observations do not support the
atients
%)
Quartile 3
(55.84%–70.25%)
Quartile 4
(>70.25%) p Value
5 (15.6) 8 (27.6) 0.009
5 (15.6) 7 (24.1) 0.023
1 (3.1) 1 (3.4) 1.000
2 (6.3) 1 (3.4) 0.906
3 (9.4) 2 (6.9) 0.784
0 (0) 1 (3.4) 0.562
2 (6.3) 2 (6.9) 0.485
2 (6.3) 3 (10.3) 0.583
2 (6.3) 3 (10.3) 0.110
4 (12.6) 6 (20.6) 0.061
9 (28.1) 9 (31) 0.132
ole PopulationCE in the Whole Population
MACE
p Value HR (95% CI) p Value
0.287 1.00 (0.99–1.02) 0.375
0.137 0.98 (0.57–1.67) 0.940
0.085 1.37 (0.85–2.20) 0.184
0.622 1.02 (0.63–1.63) 0.932
0.629 0.92 (0.57–1.47) 0.733
0.116 0.64 (0.40–1.08) 0.071
0.728 1.36 (0.85–2.17) 0.194
0.775 0.77 (0.39–1.51) 0.463
0.293 1.41 (0.61–3.27) 0.416
0.001 1.25 (0.77–2.04) 0.353
0.450 1.37 (0.85–2.21) 0.192
0.524 0.86 (0.52–1.44) 0.580
0.313 1.99 (1.01–3.91) 0.045
0.106 0.44 (0.22–0.84) 0.014
0.001 3.05 (1.56–5.99) 0.001
0.640 1.65 (1.02–2.65) 0.038
0.293 1.23 (0.72–2.04) 0.439
0.005 1.64 (1.01–2.67) 0.044
0.626 1.94 (0.70–5.33) 0.198
0.008 1.54 (0.96–2.45) 0.069KD P
tile 2
–55.83
.3)
.3)
.3)
.3)
.3)
)
.3)
.3)
)
.3)
0)e WhMA
eathary artery; LR low response to clopidogrel; PCI percutaneous intervention; other abbreviations
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o CKD. However, given the limited number of patients
ith severe CKD enrolled in the present registry, we could
ot definitely exclude that an altered platelet response to
lopidogrel occurs in these clinical settings.
mpact of low platelet response to clopidogrel in CKD
atients. In our registry, the interaction between CKD and
ow response to clopidogrel was associated with an increased
isk of cardiac death at 9 months. Of note, the prognosis of
KD with a normal response to clopidogrel appears com-
arable to that observed in patients with preserved eGFR.
nterestingly, the Kaplan-Meier curve profile suggests a late
atch-up with similar MACE rates after 400 days (Fig. 3).
his observation might indicate that the impact on MACE
f the responsiveness to clopidogrel is less important in
KD patient in the late follow-up after PCI. However,
ince cardiovascular mortality (Fig. 2) still increases between
roups even after 300 days, late follow-up of our data should
e interpreted with caution. Additional study on a larger
ohort and longer follow-up should be performed. This
bservation might suggest that the achievement of optimal
2Y12 platelet inhibition, especially in the first year, is an
mportant therapeutic goal in CKD patients. Although
everal studies have emphasized the deleterious impact of
ow platelet inhibition by thienopyridines on worsened
ardiovascular outcome in unselected patients, the question
f whether impaired platelet inhibition by thienopyridines
pecifically impairs cardiovascular prognosis was not inves-
igated in CKD patients. In this setting, the benefit of
hienopyridines is still controversial (36). Indeed, after PCI,
ost hoc analyses of the CREDO (Clopidogrel for the
eduction of Events During Observation) trial have sug-
ested that in patients with mild or moderate CKD (cor-
esponding to stages II and III), clopidogrel may not have
he same beneficial effect as in patients with normal renal
unction. In patients with normal renal function treated for
year with clopidogrel, the rate of MACE (death, myocar-
ial infarction, and stroke) was significantly reduced com-
ared with placebo. However, in patients with mild or
ultivariate Analysis for the Predictionf Cardiac Death and MACE Following PCITable 9 Multivariate Analysis for the Predictionof Cardiac Death and MACE Following PCI
HR (CI) p Value
Cardiac Death
Killip class III–IV 3.56 (1.26–10.03) 0.016
Drug-eluting stent 4.13 (1.30–13.05) 0.016
PRI 61% 0.76 (0.14–4.18) 0.758
CKD 0.89 (0.16–5.01) 0.901
PRI 61% (LR) 11.96 (1.22–116.82) 0.033
MACE
Planned PCI 0.47 (0.24–0.92) 0.029
Drug-eluting stent 1.89 (1.14–3.11) 0.012
PRI 61% (LR) 2.36 (1.35–4.15) 0.003
R  low responder; other abbreviations as in Tables 2 and 8.oderate CKD, clopidogrel therapy was not associated with tignificant benefit (37). This negative result in CKD pa-
ients might be related to the relatively low dose of clopi-
ogrel in this trial (loading dose 300 mg, maintenance dose
5 mg). The interindividual variability of the platelet
esponse to a loading dose (300 mg) or to the long-term
ose of 75 mg/day has been clearly demonstrated. In our
xperience, such a regimen is associated with a prevalence of
atients with low platelet P2Y12 inhibition of approximately
0% to 40% (38,39). It is reasonable to speculate that a more
otent P2Y12 inhibition may favorably affect the poor
rognosis of CKD patients. Indeed, in TRITON–TIMI 38
Trial to Assess Improvement in Therapeutic Outcomes by
ptimizing Platelet Inhibition With Prasugrel–Thrombolysis
n Myocardial Infarction 38), the reduction in the risk of
tent thrombosis (definite/probable) associated with prasug-
el use was independent of the presence of CKD (40,41).
Taken together, our data suggest that the evaluation of
he platelet responsiveness to clopidogrel using the VASP
ssay might be of great value for the management of CKD
atients treated by PCI. In addition, in CKD patients
reated by PCI, optimal inhibition of the P2Y12 pathway
ould be an important target to reduce ischemic events. This
ypothesis needs further evaluation, especially in light of the
escribed increased bleeding associated with more drastic
2Y12 inhibition or renal insufficiency.
tudy limitations. Single time-point laboratory assessment
epresents a common limitation to most studies assessing
he prognostic implication of platelet function or other
iological variables such as serum creatinine. The impact of
ontrast toxicity that may account to worsen clinical out-
ome after PCI was not investigated. The timing of the
ASP analysis was not uniform. VASP testing was not
ompared in this study with other techniques of platelet
unction. We could not exclude that a disproportionate
oncompliance to clopidogrel in CKD low responder pa-
ients could have affected the cardiovascular outcome. The
otential impact of increasing the doses of clopidogrel has
ot been investigated in patients detected as low responders.
tent implantation (bare-metal stents vs. DES) was not
andomized. The cardiovascular events were not adjudicated
y an independent committee. Given the relatively low
umber of cardiovascular death recorded in this registry,
ultivariate analysis should be interpreted with caution and
he findings viewed as exploratory and/or hypothesis gen-
rating. As with similar evaluation of registry data, there are
nherent limitations in this type of study, mainly related to
nown or unknown confounding factors.
onclusions
aken together, our data suggest that the presence of low
latelet response to clopidogrel is associated with worse
utcome after PCI in patients with CKD. The evaluation of
he responsiveness to clopidogrel using the VASP assay
ould be useful for the management of CKD patients
reated by PCI. A possible beneficial impact of more potent
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r ticagrelor (42) needs further evaluation.
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